{"filings":[{"id":2051363,"accession_number":"0000879407-26-000058","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-08-04T20:03:02+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.","Plozasiran Phase 3 SHASTA-3/4: 79% and 81% median triglyceride reductions; 78% reduction in acute pancreatitis events.","Acquired FDA priority review voucher for plozasiran sNDA in sHTG, expected before end of 2026.","Exclusive license to Madrigal for ARO-PNPLA3: $25M upfront, up to $975M milestones, tiered royalties.","REDEMPLO prescriptions roughly doubled in Q3; >400 prescribers; EU and Australia marketing authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":413023000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083637,"accession_number":"0000879407-26-000050","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-06-16T20:02:56+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Dr. Matt Cohen to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Matt Cohen, M.D., M.B.A., as director effective June 12, 2026.","Cohen is Managing Director at Vida Ventures; previously lead healthcare investor at JPMorgan for ~20 years.","Received standard non-employee director compensation plus sign-on RSU grant of $887,000 vesting over three years.","No family relationships or arrangements with any other director or officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99362,"accession_number":"0000879407-26-000045","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).","REDEMPLO launch: >400 prescriptions, ~180 patients shipped, ~30 new scripts/week, 85% APOC3-naive patients.","Licensed ARO-PNPLA3 to Madrigal for $25M upfront, up to $975M milestones, tiered royalties (high-single to mid-teens).","Raised $930M: $700M zero-coupon converts due 2032 (35% premium) and $230M stock at $64.50/sh.","Obesity: ARO-INHBE combo -9.4% weight loss wk16 (vs -4.8%); ARO-ALK7 -88% mRNA knockdown, -14.1% visceral fat."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":337770000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115315,"accession_number":"0000879407-26-000037","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.","Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.","Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.","KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.","All other directors elected with over 90% support from votes cast (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115314,"accession_number":"0000879407-26-000033","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.","REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.","Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.","Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.","Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":264033000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115313,"accession_number":"0001193125-26-010582","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Arrowhead issues $700M zero-coupon convertible notes due 2032; enters capped call to reduce dilution","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Arrowhead issued $700M 0.00% convertible senior notes due 2032; conversion price ~$87.07 per share.","Entered capped call transactions costing ~$47.9M to reduce potential dilution from conversion.","Underwriters' over-allotment option of $75M fully exercised; total notes issued $700M.","Notes mature Jan 15, 2032; no regular interest; special interest up to 0.50% for reporting failures.","Initial conversion rate 11.4844 shares per $1,000 principal; redeemable after Jan 16, 2029 under conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115312,"accession_number":"0001193125-26-007971","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.","Net proceeds of ~$216.6M from equity offering: 3.1M shares at $64.50 plus pre-funded warrants for 1.55M shares.","Notes convertible at initial price of ~$87.07 (35% premium); capped call transactions entered to reduce dilution.","Proceeds for general corporate purposes, R&D, commercialization, and potential prepayment of Sixth Street credit facility.","Offerings priced Jan 7, 2026; equity closes Jan 9, notes close Jan 12, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115311,"accession_number":"0000879407-26-000004","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Arrowhead reports Phase 1/2a data: ARO-INHBE + tirzepatide doubles weight loss in obese T2DM patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.","ARO-INHBE monotherapy: single dose reduced visceral fat -9.9% at week 16; two doses gave -15.6% placebo-adjusted at week 24.","ARO-ALK7 is first RNAi to silence an adipocyte gene; mean ALK7 mRNA reduction -88% at 200 mg; visceral fat -14.1% at week 8.","Both candidates generally well tolerated; no discontinuations; one unrelated SAE (limb abscess) in ARO-INHBE group.","Company expects additional results from these ongoing Phase 1/2a studies later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131731,"accession_number":"0000879407-25-000027","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.","FDA approved REDEMPLO (plozasiran) for FCS—first approved siRNA for the rare disease; self-administered quarterly.","Novartis licensing agreement for ARO-SNCA: $200M upfront, up to $2B milestones, low double-digit royalties.","Sarepta paid $300M milestones; $100M settled with cash and Arrowhead stock buyback at $18.79 per share.","Net loss attributable to Arrowhead: ($1.6M) vs ($599M) prior year; cash resources $919.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":829448000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131730,"accession_number":"0000879407-25-000019","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.","Phase 3 PALISADE study showed 80% median triglyceride reduction vs 17% placebo and lower acute pancreatitis incidence.","REDEMPLO is first FDA-approved siRNA medicine for FCS, self-administered quarterly at home.","Approximately 6,500 people in the U.S. live with genetic or clinical FCS.","Arrowhead's first FDA-approved medicine marks transition to a commercial-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148307,"accession_number":"0000879407-25-000010","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis sues Arrowhead for patent infringement over plozasiran, threatening FCS launch","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Ionis filed complaint in Central District of California alleging Arrowhead's plozasiran infringes U.S. Patent No. 9,593,333.","Arrowhead had preemptively sought declaratory judgment in Delaware to invalidate the same patent on Sept. 10, 2025.","Arrowhead expects FDA decision on plozasiran NDA by Nov. 18, 2025 (PDUFA) and plans Q4 2025 launch.","The '333 patent covers method of reducing triglycerides in adults with familial chylomicronemia syndrome (FCS).","Ionis says it sent a pre-suit notice on Sept. 3, 2025; Arrowhead did not engage before filing DJ action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148306,"accession_number":"0000879407-25-000007","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arrowhead files declaratory judgment suit against Ionis over '333 patent for plozasiran","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arrowhead filed a declaratory judgment action in Delaware against Ionis claiming the '333 patent is invalid and not infringed by plozasiran.","Plozasiran is Arrowhead's RNAi therapy for familial chylomicronemia syndrome (FCS); Phase 3 PALISADE study showed up to 80% triglyceride reduction.","FDA PDUFA action date for plozasiran is November 18, 2025.","Ionis sent a September 3, 2025 letter alleging patent infringement and threatening suit; Arrowhead acted preemptively.","Arrowhead's complaint alleges the '333 patent claims are invalid for anticipation and lack of written description/enablement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148305,"accession_number":"0000879407-25-000004","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.","Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).","Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.","Arrowhead eligible for tiered royalties up to low double digits on net product sales.","Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148304,"accession_number":"0001628280-25-038867","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).","Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.","Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.","Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.","Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":572976000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167087,"accession_number":"0001628280-25-024675","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).","GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.","FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.","CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.","Cash and investments $1.097B; company funded into 2028 with no near-term equity needs."],"consensus_eps_estimate":-1.0456,"consensus_eps_actual":1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":545209000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167086,"accession_number":"0001628280-25-017844","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.","Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.","Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.","Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.","CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184454,"accession_number":"0001628280-25-013619","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead shareholders elect eight directors, approve executive compensation, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with majority support; Douglas Ingram received 68.9M for vs 13.8M against.","Advisory vote to approve executive compensation passed with 75.3M for, 7.4M against.","Advisory vote on frequency of future say-on-pay selected 1 year with 79.9M votes.","Ratification of KPMG as independent auditors approved with 101.0M for, 1.2M against.","Over 102.7M shares voted out of 125.1M outstanding; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184453,"accession_number":"0001628280-25-004637","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.","Sarepta collaboration: $825M upfront ($500M cash + $325M equity at $27.25/share, 35% premium), plus $250M over 5 years, up to $10B milestones.","Plozasiran NDA for familial chylomicronemia syndrome accepted; PDUFA date Nov 18, 2025.","Phase 3 PALISADE met primary endpoint; plozasiran reduced triglycerides up to 86% and acute pancreatitis.","Cash & investments $552.9M; company funded into 2028; obesity programs (ARO-INHBE, ARO-ALK7) entering Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":2500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184452,"accession_number":"0001628280-25-004313","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Sarepta CEO Douglas Ingram as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.","Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.","He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.","Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201045,"accession_number":"0001628280-24-051729","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead Chairman Dr. Given to retire; Sarepta CEO Ingram expected to join board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Douglass Given retires from Board effective Dec 31, 2024, after 14 years as Chairman.","Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join Board in Q1 2025.","Ingram's appointment aligns with closing of Arrowhead-Sarepta Exclusive License and Collaboration Agreement (Nov 25, 2024).","Company expresses gratitude for Dr. Given's service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201044,"accession_number":"0001628280-24-049281","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.","Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.","Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.","Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.","Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217055,"accession_number":"0001628280-24-036113","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 net loss $170.8M ($1.38/sh); secures $500M credit facility; plozasiran Phase 3 meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.","Secured $500M non-dilutive credit facility from Sixth Street ($400M funded, $100M available) plus $50M milestone from Royalty Pharma.","Pivotal Phase 3 PALISADE study of plozasiran in FCS met primary endpoint: triglycerides reduced up to 80%, APOC3 up to 94%, acute pancreatitis incidence reduced vs placebo.","Initiated Phase 3 SHASTA-3/4 for plozasiran in severe hypertriglyceridemia; plans for Phase 3 CAPITAN cardiovascular outcomes trial.","Cash and investments $436.7M at June 30, 2024, up from $403.6M at Sept 30, 2023; company approaching plozasiran launch in 2025 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236824,"accession_number":"0001628280-24-022233","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 net loss $125.3M ($1.02/share) vs prior year net income $48.7M; revenue $0","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $125.3 million ($1.02 diluted loss per share) compared to net income of $48.7 million ($0.45 diluted EPS) in Q2 2023.","Revenue was $0, down from $146.3 million a year ago, with no milestone or collaboration revenue recorded.","R&D expenses rose to $101.1 million from $74.9 million; cash and investments totaled $523.1 million, boosted by $450 million stock offering.","Received $50 million milestone from Royalty Pharma in Q3 for olpasiran Phase 3 enrollment completion (Amgen-conducted trial).","Positive Phase 2 SHASTA-2 plozasiran data: 90.6% of patients achieved triglycerides <500 mg/dL at week 24."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254435,"accession_number":"0001628280-24-011930","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead shareholders elect 7 directors, approve exec pay, ratify KPMG at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 76.4M (Given) to 84.3M (Anzalone), with ~19.3M broker non-votes.","Advisory vote on executive compensation passed with 82.6M for, 4.95M against, 143k abstain.","Ratification of KPMG as independent auditor for FY2024 passed with 104.1M for, 2.6M against, 366k abstain.","Record date Jan 19, 2024; 106.99M of 123.84M shares voted at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254430,"accession_number":"0001628280-24-011557","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K/A","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Hongbo Lu to board; board expands to eight, effective March 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hongbo Lu appointed to Arrowhead Board; board expanded from seven to eight, effective March 15, 2024.","Dr. Lu receives sign-on RSU grant of $761,666, vesting over three years.","Dr. Lu will receive standard non-employee director compensation as described in the 2024 proxy statement.","Dr. Lu has no family relationships with executives and no material interest in any related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254434,"accession_number":"0001628280-24-005998","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Hongbo Lu to board; expands to 8 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hongbo Lu, Ph.D., appointed as independent director effective April 1, 2024, increasing board from 7 to 8.","Lu brings over 20 years of healthcare investment experience, including Managing Partner at Vivo Capital and LAV.","She receives standard non-employee director compensation plus sign-on RSU grant valued at $761,666 vesting over three years.","No family relationships or material interests with Arrowhead directors or officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254433,"accession_number":"0001628280-24-003488","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead reports Q1 revenue of $3.55M, down 94% YoY; operating loss $136.5M; cuts cash burn by up to $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.55M vs $62.55M YoY; net loss $132.9M ($1.24 EPS) from $41.3M ($0.39 EPS) loss prior year.","Operating expenses $140.1M (R&D $116.5M, G&A $23.6M); operating loss $136.5M.","Cuts forward cash burn guidance by up to $100M (~$30M/qtr); completed $450M stock offering.","Terminated ARO-SOD1 and HZN-457; focuses on cardiometabolic, pulmonary programs; hired interim chief medical scientist."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254432,"accession_number":"0001628280-24-001805","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead CMO Javier San Martin departing Feb 1; Bruce Given returns as Chief Medical Scientist","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Javier San Martin, Chief Medical Officer, leaves Arrowhead effective February 1, 2024.","Bruce Given, retired former COO and R&D head, appointed Chief Medical Scientist to ensure orderly transition.","Company thanks San Martin for his contributions as CMO and executive team member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254431,"accession_number":"0001628280-24-000480","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arrowhead prices 15.79M share offering at $28.50, expects net proceeds of $429.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales of 15,790,000 shares at $28.50/share; net proceeds ~$429.0M after discounts and expenses.","Underwriters include Jefferies, BofA Securities, and Cowen and Company as representatives.","Proceeds allocated to R&D, general corporate expenses, and working capital needs.","Offering expected to close on January 5, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271913,"accession_number":"0001628280-23-040776","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Arrowhead Pharmaceuticals dismisses RSJ as auditor, engages KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Rose, Snyder & Jacobs (RSJ) as independent auditor effective December 1, 2023.","RSJ's audit reports for FY2022 and FY2023 were unqualified with no adverse opinion.","No disagreements or reportable events occurred in the two fiscal years or subsequent interim period.","Engaged KPMG as new independent auditor for fiscal year ending September 30, 2024.","Company did not consult KPMG on accounting principles, disagreements, or reportable events prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271912,"accession_number":"0001628280-23-040222","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).","Cash and investments $403.6M, down from $482.3M; R&D spend up 19% to $353M.","Plozasiran (APOC3) showed up to 90% APOC3 reduction in Phase 2 severe hypertriglyceridemia.","Completed GLP tox for pulmonary candidates ARO-RAGE and ARO-MMP7; planning Phase 2.","GSK acquired full rights to JNJ-3989 (ARO-HBV) from Janssen; Arrowhead retains no further obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":240735000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288759,"accession_number":"0001628280-23-027779","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 net loss widens to $103M; revenue drops 51%; milestones from GSK and Takeda","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.8M (down 51% YoY from $32.4M); net loss $102.9M (vs $72.0M loss); diluted EPS -$0.96 (vs -$0.68).","Cash and investments $494.5M vs $482.3M at Sept 30, 2022; total assets $795.9M.","Earned $30M milestone from GSK for Phase 2b start of ARO-HSD (NASH); $40M from Takeda for first patient in Phase 3 REDWOOD of fazirsiran.","Completed enrollment of PALISADE Phase 3 for ARO-APOC3; data readout expected Q2 2024.","R&D Day: ARO-RAGE inhaled dose of 184mg achieved 90% mean knockdown; TRiM platform shows CNS and adipose delivery advances."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":224638000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309417,"accession_number":"0001628280-23-014859","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.","Earned $40M milestone from Takeda for fazirsiran Phase 3 start; $30M from GSK for Phase 2b of GSK4532990 (NASH).","Phase 1/2 ARO-RAGE: mean max 80% reduction in serum sRAGE after two 92 mg doses; no serious AEs; supports lung delivery platform.","Regained rights to ARO-PNPLA3 from Janssen; FDA Fast Track for ARO-APOC3 for familial chylomicronemia syndrome.","Cash and investments $559.8M vs $482.3M at Sept 30, 2022; R&D Day June 1, 2023; ARO-SOD1 on track for Q3 CT filing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":208813000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328148,"accession_number":"0001628280-23-008639","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arrowhead shareholders elect eight directors, approve executive compensation and share increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; votes ranged from ~62.8M to ~67.8M in favor.","Advisory vote on executive compensation passed with 62,683,718 for, 7,119,440 against.","Amendment to increase authorized common shares approved: 80,352,213 for, 8,279,373 against.","Ratification of Rose Snyder & Jacobs as auditors passed: 86,613,251 for, 1,296,520 against.","Broker non-votes of ~18.7M were recorded on director election and executive compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328147,"accession_number":"0001628280-23-003635","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Arrowhead Regains Full Rights to ARO-PNPLA3 After Janssen Terminates Collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janssen terminated the Research Collaboration and Option Agreement with Arrowhead effective April 7, 2023.","Arrowhead regains all rights and licenses to ARO-PNPLA3 (formerly JNJ-75220795), a NASH candidate.","Phase 1 data showed up to 40% mean reduction in liver fat in PNPLA3 I148M homozygotes after a single dose.","No serious adverse events reported; safety profile encouraging with mostly mild AEs.","Arrowhead plans to design a Phase 2 study and assess options for communicating full Phase 1 results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328146,"accession_number":"0001628280-23-003560","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Marianne De Backer resigns from Arrowhead board effective April 2, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marianne De Backer notified Arrowhead of her resignation as director, effective April 2, 2023.","De Backer served as independent director, on Audit, Compensation, and as Chair of Nomination Committee.","Resignation due to her appointment as CEO and director of Vir Biotechnology; no disagreement with Arrowhead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328145,"accession_number":"0001628280-23-002660","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arrowhead Pharmaceuticals clarifies shares outstanding as of February 1, 2023","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Filed an 8-K on February 7, 2023 to clarify that shares outstanding as of February 1, 2023 were 106,710,568.","The clarification follows the filing of the quarterly report on Form 10-Q for the first quarter of fiscal 2023 on February 6.","The company's common stock is listed on Nasdaq under ticker ARWR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328144,"accession_number":"0001628280-23-002417","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Pharma Q1 revenue $62.5M, net loss narrows to $0.39; sells olpasiran royalty for $250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $62.5M vs $27.4M; net loss $41.3M ($0.39/share) improved from $62.9M ($0.60).","Total cash and investments $617.6M at Dec 31, up from $482.3M at Sep 30.","Earned $25M milestone from Amgen for olpasiran Phase 3 start, $15M from Horizon for HZN-457 Phase 1 start.","Sold olpasiran royalty interest to Royalty Pharma for $250M upfront plus up to $160M contingent payments.","Topline SEQUOIA study: fibrosis regression in 50% of fazirsiran-treated AATD patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":62546000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328143,"accession_number":"0001628280-23-001757","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Arrowhead amends bylaws to add proxy access, update stockholder nomination rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Second Amended and Restated Bylaws effective January 24, 2023.","Adds proxy access: stockholder or group of up to 20 owning 3% for 3 years may nominate up to 20% of board or two directors.","Updates procedural mechanics for stockholder nominations and business proposals.","Requires a proxy card color other than white for stockholders soliciting proxies from others.","Conforms bylaws to recent Delaware General Corporation Law amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345799,"accession_number":"0001628280-22-031597","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arrowhead Pharmaceuticals raises ~$250M via equity offering of 7.8M shares through Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies LLC to sell up to 7,807,620 shares of common stock.","Estimated gross proceeds of ~$250 million after discounts, commissions, and expenses.","Offering closed on December 2, 2022; shares issued under shelf registration statement on Form S-3.","Company agreed to indemnify Jefferies against certain liabilities under the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345798,"accession_number":"0001628280-22-030866","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.","Net loss $172.7M ($1.67 diluted loss per share) vs $140.8M ($1.36) prior year.","Sold olpasiran royalty interest to Royalty Pharma for $250M cash plus up to $160M milestones.","Phase 2 studies for ARO-APOC3 and ARO-ANG3 fully enrolled; new Phase 1/2a starts for ARO-MUC5AC, ARO-RAGE, ARO-MMP7.","Cash and investments $482.3M at Sep 30, 2022, down from $613.4M at Sep 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":243231000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345797,"accession_number":"0001628280-22-029456","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.","Up to $160M in milestones: $50M on Phase 3 enrollment, $50M on FDA approval, $60M after annual royalty receipt threshold.","Arrowhead retains eligibility for all milestone payments from Amgen under the original license agreement.","Transaction provides non-dilutive cash to fund Arrowhead's pipeline and operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362219,"accession_number":"0001628280-22-021061","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.","Total cash & investments $582.4M, down from $613.4M at Sept 2021; operating loss $72.9M.","Phase 2 fazirsiran: fibrosis regression in 58%, median 83% reduction in Z-AAT accumulation in liver.","Initiated Phase 1/2a for ARO-MUC5AC and ARO-RAGE; Phase 2 GATEWAY for ARO-ANG3 in HoFH started.","Hired Tracie Oliver as CCO; promoted Patrick O'Brien to COO; formed JV Visirna Therapeutics with Vivo Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":211656000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362218,"accession_number":"0001628280-22-019124","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arrowhead appoints Patrick O'Brien as COO and General Counsel effective July 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick O'Brien (age 59) named Chief Operating Officer and General Counsel, effective July 15, 2022.","He retains roles as Chief Compliance Officer and Corporate Secretary.","O'Brien joined Arrowhead in December 2014 and previously served as General Counsel.","Over 25 years healthcare legal experience, including positions at Shire, Johnson & Johnson, and the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381742,"accession_number":"0001628280-22-016371","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arrowhead retains three directors who failed to win majority vote at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Perry, Ferrari, and Waddill each received less than a majority of votes for re-election on March 17, 2022.","The Nominating Committee and Board unanimously rejected their resignation offers, citing qualifications and board composition.","Primary reason for vote outcome was shareholder concern over executive compensation programs.","All three directors will continue serving until the 2023 annual meeting or until successors are elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381741,"accession_number":"0001564590-22-019267","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.","Initiated PALISADE Phase 3 study of ARO-APOC3 in familial chylomicronemia syndrome; completed enrollment of 204 patients in Phase 2b ARCHES-2 for ARO-ANG3.","Formed Visirna Therapeutics joint venture with Vivo Capital to expand into Greater China.","Broke ground on new manufacturing facility; awarded up to $18.5M in tax incentives from Wisconsin and Verona.","Total cash and investments of $603.5M as of March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":179244000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381740,"accession_number":"0001193125-22-142093","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arrowhead appoints Victoria Vakiener to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Victoria Vakiener appointed effective May 2, 2022, as independent director.","She has extensive biotech/commercial experience; former CCO of Epizyme and 20+ years at J&J.","Granted 17,181 restricted stock units vesting over three years as standard director comp.","Ms. Vakiener also serves on board of Chimerix, a clinical-stage biopharma company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381739,"accession_number":"0001193125-22-116331","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arrowhead forms JV with Vivo Capital for Greater China; licenses four RNAi cardiometabolic drugs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vivo Capital provided $60M initial funding to Visirna Therapeutics, JV in which Arrowhead holds majority stake.","Visirna gets exclusive rights to develop and commercialize four investigational RNAi therapeutics in Greater China.","Arrowhead eligible to receive royalties on net commercial sales in the licensed territory.","Vivo Capital's Hongbo Lu and Gaurav Aggarwal to join Visirna board; Arrowhead also appoints board members.","Visirna to be headquartered in Shanghai; recruitment of management and staff underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399723,"accession_number":"0001193125-22-079575","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arrowhead shareholders reject advisory pay plan and director comp plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on executive compensation: 54.8M against vs 14.2M for; proposal fails.","Non-Employee Director Compensation Plan: 52.5M against vs 16.0M for; proposal fails.","Three directors (Ferrari, Perry, Waddill) received majority AGAINST votes (44.4M, 39.8M, 42.7M resp.).","Ratification of auditors (Rose Snyder & Jacobs) passed with 87.2M votes for.","Approx. 20.2M broker non-votes on all proposals except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399722,"accession_number":"0001564590-22-003608","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.","Revenue rose to $27.4M from $21.3M, primarily from license and collaboration revenue.","R&D expense nearly doubled to $65.8M; G&A expense tripled to $25.0M.","Initiated PALISADE Phase 3 study for ARO-APOC3 in familial chylomicronemia syndrome.","Entered exclusive license with GSK for ARO-HSD (NASH); advanced two pulmonary candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":27439000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-02T23:59:59+00:00|399722"}